drugset / Trial / NCT02245620

A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly

NCT02245620

Phase 2 Completed 41 enrolled Stealth BioTherapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This was a Phase 2, randomized, double-blind, placebo-controlled study, enrolling 41 elderly subjects with previous evidence of mitochondrial dysfunction to evaluate whether the administration of MTP-131 (elamipretide) will change either hand skeletal muscle energetics or muscle performance in age-related skeletal muscle mitochondrial dysfunction.

Timeline

Start
2015-01-15
Primary completion
2016-07-06
Completion
2016-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 0.25 mg/kg Intravenous